Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
MNTA [NASD]
Momenta Pharmaceuticals Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.54 Insider Own2.38% Shs Outstand51.93M Perf Week2.76%
Market Cap695.34M Forward P/E- EPS next Y-1.52 Insider Trans8.80% Shs Float45.95M Perf Month3.72%
Income-77.78M PEG- EPS next Q-0.46 Inst Own82.00% Short Float6.05% Perf Quarter6.69%
Sales47.30M P/S14.70 EPS this Y-132.78% Inst Trans0.64% Short Ratio9.08 Perf Half Y25.85%
Book/sh6.57 P/B2.04 EPS next Y20.00% ROA-18.58% Target Price14.80 Perf Year-5.10%
Cash/sh6.24 P/C2.14 EPS next 5Y- ROE-20.96% 52W Range10.05 - 17.09 Perf YTD13.57%
Dividend- P/FCF- EPS past 5Y0.00% ROI-19.48% 52W High-21.65% Beta1.34
Dividend %- Quick Ratio- Sales past 5Y24.28% Gross Margin- 52W Low33.23% ATR0.39
Employees247 Current Ratio20.74 Sales Q/Q-68.62% Oper. Margin-167.59% RSI (14)60.06 Volatility2.80% 3.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-380.30% Profit Margin-164.46% Rel Volume0.42 Prev Close13.31
ShortableYes LT Debt/Eq0.00 EarningsApr 30 BMO Payout- Avg Volume306.21K Price13.39
Recom2.50 SMA207.27% SMA503.20% SMA2003.25% Volume127,305 Change0.60%
27-Jan-12Reiterated Canaccord Genuity Buy $17
20-Sep-11Reiterated Wedbush Outperform $29 → $24
20-Sep-11Reiterated Canaccord Genuity Buy $27 → $15
15-Apr-11Initiated UBS Neutral $17
26-Jan-11Reiterated Rodman & Renshaw Mkt Outperform $32 → $22
02-Nov-10Reiterated Oppenheimer Outperform $34 → $32
26-Aug-10Reiterated Rodman & Renshaw Mkt Outperform $24 → $32
26-Jul-10Reiterated Wedbush Outperform $20 → $29
13-May-10Reiterated Oppenheimer Outperform $17 → $19
19-Nov-09Upgrade Oppenheimer Perform → Outperform $15
18-Nov-09Initiated Canaccord Adams Buy
18-Sep-09Initiated Deutsche Securities Buy $15
19-May-09Initiated Wedbush Morgan Buy $15
13-Feb-09Upgrade Stanford Research Hold → Buy $17
05-Jan-09Initiated Leerink Swann Outperform $16
08-May-08Downgrade Bear Stearns Outperform → Peer Perform
29-Apr-08Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $30
21-Feb-08Reiterated Deutsche Securities Hold $6 → $8
07-Nov-07Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
07-Nov-07Downgrade Deutsche Securities Buy → Hold
23-May-13 04:30PM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
22-May-13 02:09PM  Momenta Pharmaceuticals Management Presents at 2013 UBS Global Healthcare Conference (Transcript) at Seeking Alpha
12:56PM  Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry at Seeking Alpha
17-May-13 01:04PM  MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials
16-May-13 12:17AM  Momenta Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
13-May-13 04:36PM  Momenta Pharmaceuticals (MNTA) Shares Cross Above 200 DMA at TheStreet
10-May-13 05:03AM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online +7.49%
09-May-13 04:30PM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
02-May-13 12:00PM  5 Names Seeing Bullish Options Flow at TheStreet
11:25AM  Big Generic Drug Players See Best Topline Growth Rates in Emerging Markets: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street Transcript Wall Street Transcript
30-Apr-13 02:50PM  Momenta Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
12:39PM  Oversold Conditions For Momenta Pharmaceuticals (MNTA) at TheStreet
11:04AM  Momenta Pharmaceuticals Earnings: Heres Why Shares are Down Now at Wall St. Cheat Sheet
08:00AM  Momenta Pharmaceuticals Reports First Quarter 2013 Financial Results GlobeNewswire
07:07AM  Q1 2013 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
01:41AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
29-Apr-13 01:07PM  3 Biotech Companies for Young Investors at Motley Fool
22-Apr-13 12:30PM  Momenta Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For MNTA at TheStreet
09-Apr-13 04:15PM  Momenta Pharmaceuticals Announces Date of First Quarter 2013 Financial Results Conference Call and Webcast GlobeNewswire
27-Mar-13 08:40AM  Stocks With Upcoming Legal Catalysts at Seeking Alpha
14-Mar-13 11:34AM  Momenta Pharmaceuticals Management Presents at Barclays Healthcare Conference - Transcript at Seeking Alpha
13-Mar-13 06:56AM  New Drugs Tempt Lupin to Spend Up to $1 Billion: Corporate India at Bloomberg
12-Mar-13 02:32PM  New Drugs Tempt Lupin to Spend Up to $1 Billion: Corporate India at Bloomberg
10-Mar-13 01:34AM  Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg
07-Mar-13 09:40AM  Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg
05:15AM  Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg
04:44AM  Teva Advances as Savings May Offset Competition: Tel Aviv Mover at Bloomberg
06-Mar-13 01:04PM  MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials
28-Feb-13 04:29PM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
26-Feb-13 08:47AM  Momenta taps into emerging market of biosimilars at bizjournals.com
25-Feb-13 04:30PM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
22-Feb-13 01:15PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
19-Feb-13 03:58PM  Loss at MNTA Narrower than Expected Zacks
18-Feb-13 07:51PM  New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine
15-Feb-13 02:20PM  Momenta Pharmaceuticals CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
02:12PM  Momenta Pharmaceuticals sticks to guidance despite revenue plunge at bizjournals.com
10:57AM  Momenta Pharmaceuticals Earnings: Heres Why Investors are Happy Now at Wall St. Cheat Sheet
09:34AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
08:08AM  Momenta Pharma stills sees 2013 operating cash use about $90M theflyonthewall.com
08:02AM  InPlay: Momenta Pharma beats by $0.07, beats on revs Briefing.com
08:00AM  Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial Results GlobeNewswire
07:07AM  Q4 2012 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07-Feb-13 11:24AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
09:00AM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
04-Feb-13 11:00PM  3 Things to Watch at Momenta Pharmaceuticals at Motley Fool
28-Jan-13 09:24PM  Biotech Firms, Billions at Risk, Lobby States to Limit Generics at New York Times
09:24PM  Battle in States on Generic Copies of Biotech Drugs at New York Times
09:24PM  Battle in States on Generic Copies of Biotech Drugs at New York Times
24-Jan-13 08:30AM  Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2012 Financial Results Conference Call and Webcast GlobeNewswire
09-Jan-13 02:02PM  Biotech's a Buy, but Hold Off on HMOs: Fund Manager at CNBC
02-Jan-13 11:26AM  2013 Should Be Interesting for Multiple Sclerosis Drugs at Motley Fool
06-Dec-12 02:53PM  The Worst of 2012: Momenta Pharmaceuticals at Motley Fool
04-Dec-12 07:26PM  Momenta Pharmaceuticals' Management Presents at Deutsche Bank 2012 dbAccess BioFEST Conference (Transcript) at Seeking Alpha
03-Dec-12 04:09AM  Momenta Pharmaceuticals Inc. Stock Downgraded (MNTA) at TheStreet
30-Nov-12 06:33PM  Teva Guides for Disappointment at Motley Fool
27-Nov-12 04:30PM  Momenta Pharmaceuticals to Present at the Deutsche Bank 2012 dbAccess BioFEST GlobeNewswire
24-Nov-12 03:58PM  Hatching Ideas, and Companies, by the Dozens at M.I.T. at New York Times
20-Nov-12 12:41PM  InPlay: Momenta Pharma: U.S. Court of Appeals denied Momenta Pharmaceuticals petition for rehearing en banc in "safe-harbor" case Briefing.com
12:41PM  U.S. Court of Appeals Denied Momenta Pharmaceuticals Petition for Rehearing En Banc in "Safe-Harbor" Case GlobeNewswire
15-Nov-12 05:55PM  Momenta Pharmaceuticals' Management Presents at Credit Suisse 2012 Healthcare Conference (Transcript) at Seeking Alpha
14-Nov-12 06:59PM  Momenta Pharmaceuticals' Management Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript) at Seeking Alpha
01:04PM  MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials
09-Nov-12 12:55PM  [$$] Momenta Pharmaceuticals, Apple: Money Flow Leaders (MNTA, AAPL) at The Wall Street Journal
12:55PM  Visterra lands $13M from Gates Foundation, others at bizjournals.com
08-Nov-12 04:30PM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
12:47PM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09:33AM  New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine
08:02AM  Momenta Reveals Projections and 2 Stocks Dipping to 52-Week Lows at Wall St. Cheat Sheet
07-Nov-12 06:48PM  Why Momenta Stalled at Motley Fool -8.34%
04:02PM  Momenta Pharmaceutical's CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha
09:11AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
08:16AM  Momenta Pharma CEO: Q3 royalty rev from enoxaparin sodium injection disappoints theflyonthewall.com
08:04AM  InPlay: Momenta Pharma misses by $0.24, misses on revs Briefing.com
08:00AM  Momenta Pharmaceuticals Reports Third Quarter 2012 Financial Results GlobeNewswire
07:07AM  Q3 2012 Momenta Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
01-Nov-12 06:36PM  Has Baxter International Become the Perfect Stock? at Motley Fool
19-Oct-12 09:00AM  A Refreshing Outlook - Consensus Reports on Keryx Biopharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. Marketwire
18-Oct-12 04:48PM  Momenta Pharmaceuticals Announces Date of Third Quarter 2012 Financial Results Conference Call GlobeNewswire
05-Oct-12 11:34AM  Has Teva Pharmaceutical Become the Perfect Stock? at Motley Fool
16-Sep-12 10:00AM  3 Things to Watch With Teva Pharmaceutical at Motley Fool
14-Sep-12 11:55AM  4 Low-Debt Healthcare Stocks Raking In Profits at Seeking Alpha
12-Sep-12 11:59AM  Momenta Pharmaceuticals' CEO to Present at Morgan Stanley Healthcare Conference (Transcript) at Seeking Alpha
31-Aug-12 02:26PM  A Good Start on the Biosimilar Front at Motley Fool
30-Aug-12 05:00PM  Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences GlobeNewswire
14-Aug-12 01:04PM  MOMENTA PHARMACEUTICALS INC Financials EDGAR Online Financials
10-Aug-12 04:06AM  7 Profitable Healthcare Stocks That Analysts Love at Seeking Alpha
08-Aug-12 04:01PM  Momenta to Present at the Canaccord Genuity 32nd Annual Growth Conference GlobeNewswire
09:08AM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
06-Aug-12 11:32AM  Second quarter results strongest in five years, report said at bizjournals.com
07:00AM  Momenta, Samsung, Zynga, Netflix: Intellectual Property at Bloomberg
12:00AM  Momenta, Samsung, Zynga, Netflix: Intellectual Property at Bloomberg
04-Aug-12 02:41AM  4 Small-Cap Biotech Stocks Generating Profits With Buy Ratings at Seeking Alpha
03-Aug-12 05:29PM  Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg
04:58PM  InPlay: Momenta Pharma acknowledges Federal Circuit opinion supporting order issued January 26, 2012 in ongoing suit against Amphastar Pharmaceuticals and Watson Pharmaceuticals (WPI) Briefing.com
04:56PM  Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals GlobeNewswire
02:51PM  Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg
12:32PM  Biggest Healthcare Sector Movers, Including ALXN at Investopedia
11:52AM  Momenta Loses in Appeals Court Over Watsons Lovenox Copy at Bloomberg
10:58AM  New Star Analyst Rankings for Momenta Pharmaceuticals, Inc. StarMine
02-Aug-12 05:03PM  Momentas' CEO Discusses Q2 2012 Results - Earnings Call Transcript at Seeking Alpha
Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company's complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for autoimmune and inflammatory diseases; M834 for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company's novel products comprise M402, a novel heparan sulfate mimetic that binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis; and the sialylation technology, which is a discovery program that is intended to modify immunoglobulin G antibodies in intravenous immunoglobulin, a drug to treat autoimmune and inflammatory diseases. It has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leicher BruceSVP & General CounselMay 23Sale13.031952,541109,588May 24 02:41 PM
WHEELER CRAIG APresidentMay 23Sale13.032,10927,480334,303May 24 02:40 PM
Bishop John ESenior VP, Pharmaceutical ScieMay 23Sale13.032463,205100,708May 24 02:37 PM
Roach James M.Senior VP, Development and ChiMay 23Sale13.031952,54187,558May 24 02:36 PM
Shea Richard PSVP, CFOMay 23Sale13.031952,541150,316May 24 02:25 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 23Sale13.032142,788425,421May 24 02:24 PM
Shea Richard PSVP, CFOMay 21Sale12.831972,528150,511May 22 01:34 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 21Sale12.832172,784425,635May 22 01:30 PM
Leicher BruceSVP & General CounselMay 21Sale12.831972,528109,783May 22 01:27 PM
Roach James M.Senior VP, Development and ChiMay 21Sale12.831972,52887,753May 22 01:24 PM
Bishop John ESenior VP, Pharmaceutical ScieMay 21Sale12.832503,208100,954May 22 01:19 PM
WHEELER CRAIG APresidentMay 21Sale12.832,10927,058336,412May 22 12:30 PM
Shea Richard PSVP, CFOMay 16Sale13.311461,943150,708May 20 05:06 PM
Leicher BruceSVP & General CounselMay 15Sale13.332693,586109,980May 16 11:50 AM
WHEELER CRAIG APresidentMay 15Sale13.331,68722,488338,521May 17 04:25 PM
Bishop John ESenior VP, Pharmaceutical ScieMay 15Sale13.332503,333101,204May 17 04:23 PM
Roach James M.Senior VP, Development and ChiMay 15Sale13.332172,89387,950May 17 04:22 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 15Sale13.332172,893425,852May 17 04:19 PM
Fanucci MarshaDirectorMar 15Sale14.1529,400416,0109,000Mar 18 01:55 PM
Stoner ElizabethDirectorMar 05Sale14.002,04028,56011,143Mar 07 11:21 AM
WHEELER CRAIG APresidentFeb 26Sale12.582,10926,531340,208Feb 26 03:33 PM
Roach James M.Senior VP, Development and ChiFeb 26Sale12.581922,41588,167Feb 27 11:08 AM
Shea Richard PSVP, CFOFeb 26Sale12.581732,176150,854Feb 27 11:04 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 26Sale12.581832,302426,069Feb 27 11:01 AM
Bishop John ESenior VP, Pharmaceutical ScieFeb 26Sale12.582332,931101,454Feb 27 10:55 AM
Leicher BruceSVP & General CounselFeb 26Sale12.581531,925110,249Feb 27 10:54 AM
Leicher BruceSVP & General CounselFeb 25Sale12.431892,349110,402Feb 26 03:35 PM
WHEELER CRAIG APresidentFeb 25Sale12.432,10926,215342,317Feb 26 03:33 PM
Roach James M.Senior VP, Development and ChiFeb 25Sale12.431892,34988,359Feb 27 11:08 AM
Shea Richard PSVP, CFOFeb 25Sale12.431892,349151,027Feb 27 11:04 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 25Sale12.432082,585426,252Feb 27 11:01 AM
Bishop John ESenior VP, Pharmaceutical ScieFeb 25Sale12.432402,983101,687Feb 27 10:55 AM
WHEELER CRAIG APresidentFeb 20Sale12.622,10926,616344,426Feb 21 05:26 PM
Shea Richard PSVP, CFOFeb 20Sale12.627319,225151,216Feb 21 05:23 PM
Roach James M.Senior VP, Development and ChiFeb 20Sale12.621882,37388,548Feb 21 05:19 PM
Bishop John ESenior VP, Pharmaceutical ScieFeb 20Sale12.622393,016101,927Feb 21 05:12 PM
Leicher BruceSVP & General CounselFeb 20Sale12.621882,373110,591Feb 21 04:02 PM
WHEELER CRAIG APresidentFeb 15Sale12.166,75082,080286,535Feb 19 03:45 PM
Roach James M.Senior VP, Development and ChiFeb 15Sale12.2683810,27476,636Feb 19 03:41 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 15Sale12.2683810,274415,667Feb 19 03:36 PM
Bishop John ESenior VP, Pharmaceutical ScieFeb 15Sale12.2697011,89291,166Feb 19 03:34 PM
Leicher BruceSVP & General CounselFeb 15Sale12.261,04012,75099,779Feb 19 01:25 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchDec 20Option Exercise0.997,2007,128416,505Dec 21 12:28 PM
Leicher BruceSVP & General CounselNov 27Sale10.531361,432100,144Nov 27 06:36 PM
WHEELER CRAIG APresidentNov 27Sale10.532,10922,208293,285Nov 28 10:52 AM
Shea Richard PSVP, CFONov 27Sale10.531741,832140,947Nov 28 10:48 AM
Roach James M.Senior VP, Development and ChiNov 27Sale10.531922,02277,474Nov 28 10:44 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 27Sale10.531831,927409,305Nov 28 10:37 AM
Bishop John ESenior VP, Pharmaceutical ScieNov 27Sale10.532332,45392,136Nov 28 10:32 AM
Leicher BruceSVP & General CounselNov 26Sale10.581881,989100,280Nov 27 06:36 PM
Shea Richard PSVP, CFONov 26Sale10.581881,989141,121Nov 28 10:48 AM
Roach James M.Senior VP, Development and ChiNov 26Sale10.581881,98977,666Nov 28 10:44 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 26Sale10.582062,179409,488Nov 28 10:37 AM
Bishop John ESenior VP, Pharmaceutical ScieNov 26Sale10.582392,52992,369Nov 28 10:32 AM
WHEELER CRAIG APresidentNov 26Sale10.582,10922,313295,394Nov 27 09:56 AM
Shea Richard PSVP, CFONov 21Sale10.741972,116141,309Nov 26 03:51 PM
WHEELER CRAIG APresidentNov 20Sale10.962,10923,115297,503Nov 21 11:22 AM
Roach James M.Senior VP, Development and ChiNov 20Sale10.961932,11577,854Nov 21 11:16 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 20Sale10.962112,313409,694Nov 21 10:51 AM
Bishop John ESenior VP, Pharmaceutical ScieNov 20Sale10.962442,67492,608Nov 21 10:43 AM
Leicher BruceSVP & General CounselNov 20Sale10.961932,115100,468Nov 21 12:15 PM
Stoner ElizabethDirectorOct 01Sale14.531,00014,5309,849Oct 02 06:39 PM
Bishop John ESenior VP, Pharmaceutical ScieAug 29Sale14.572,39734,92492,852Aug 30 02:05 PM
Bishop John ESenior VP, Pharmaceutical ScieAug 28Sale14.352323,32995,249Aug 30 09:57 AM
WHEELER CRAIG APresidentAug 28Sale14.212,10929,969299,612Aug 30 10:17 AM
Shea Richard PSVP, CFOAug 28Sale14.351732,483141,506Aug 30 10:10 AM
Roach James M.Senior VP, Development and ChiAug 28Sale14.351922,75578,047Aug 30 10:08 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 28Sale14.351822,612409,905Aug 30 10:03 AM
Leicher BruceSVP & General CounselAug 28Sale14.351351,937100,661Aug 29 02:21 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 23Sale13.642062,810410,087Aug 27 01:38 PM
Leicher BruceSVP & General CounselAug 23Sale13.641872,551100,796Aug 27 01:31 PM
WHEELER CRAIG APresidentAug 23Sale13.572,10928,619301,721Aug 27 02:05 PM
Shea Richard PSVP, CFOAug 23Sale13.643805,183141,679Aug 27 02:00 PM
Roach James M.Senior VP, Development and ChiAug 23Sale13.641872,55178,239Aug 27 01:49 PM
Bishop John ESenior VP, Pharmaceutical ScieAug 23Sale13.642383,24695,481Aug 27 01:37 PM
WHEELER CRAIG APresidentAug 21Sale13.632,10928,746303,830Aug 23 08:56 AM
Roach James M.Senior VP, Development and ChiAug 21Sale13.781932,66078,426Aug 23 08:54 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 21Sale13.782112,908410,293Aug 23 08:50 AM
Bishop John ESenior VP, Pharmaceutical ScieAug 21Sale13.782443,36295,719Aug 23 08:49 AM
Leicher BruceSVP & General CounselAug 21Sale13.786969,591100,983Aug 22 01:19 PM
Bishop John ESenior VP, Pharmaceutical ScieAug 10Sale13.587,485101,64695,963Aug 13 04:01 PM
Stoner ElizabethDirectorAug 01Sale14.211,01014,3529,182Aug 02 03:15 PM
Shapiro Bennett MDirectorJul 10Sale14.121,60022,5927,000Jul 11 05:21 PM
Shapiro Bennett MDirectorJun 11Sale14.844005,9367,000Jun 13 04:01 PM
Stoner ElizabethDirectorJun 04Sale14.001,02014,2808,526Jun 05 03:46 PM
WHEELER CRAIG APresidentMay 29Sale13.792,11029,097331,719May 31 10:59 AM
Bishop John ESenior VP, Pharmaceutical ScieMay 29Sale13.932333,246103,448May 31 10:54 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 29Sale13.931822,535410,504May 31 10:48 AM
Shea Richard PSVP, CFOMay 29Sale13.931732,41095,331May 31 10:40 AM
Roach James M.Senior VP, Development and ChiMay 29Sale13.931922,67578,619May 31 10:38 AM
open in yahoo | open in reuters | open in google